Patents by Inventor Wayne J. Wallis

Wayne J. Wallis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for ameliorating infusion reactions
    Patent number: 11904052
    Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: February 20, 2024
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Jeffrey P. Bechard, Wayne J. Wallis
  • METHODS FOR AMELIORATING INFUSION REACTIONS
    Publication number: 20230060006
    Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.
    Type: Application
    Filed: May 20, 2022
    Publication date: February 23, 2023
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Jeffrey P. BECHARD, Wayne J. WALLIS
  • Methods for ameliorating infusion reactions
    Patent number: 11351118
    Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 7, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Jeffrey P. Bechard, Wayne J. Wallis
  • METHODS FOR AMELIORATING INFUSION REACTIONS
    Publication number: 20190328664
    Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.
    Type: Application
    Filed: December 20, 2017
    Publication date: October 31, 2019
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Jeffrey P. BECHARD, Wayne J. WALLIS
  • COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20150017164
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Application
    Filed: August 18, 2014
    Publication date: January 15, 2015
    Inventors: Rafael A. Ponce, JR., Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Penna Rossi, Hans Otto Lennart Graffner
  • Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease
    Patent number: 8852591
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: October 7, 2014
    Assignee: Zymogenetics, Inc.
    Inventors: Rafael A. Ponce, Jr., Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Pena Rossi, Hans Otto Lennart Graffner
  • COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20080260737
    Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 23, 2008
    Inventors: Rafael A. Ponce, Wayne J. Wallis, Matthew S. Holdren, Linda Zuckerman, Alisa M. Littau, Kirk P. Van Ness, Claudia Pena Rossi, Hans Otto Lennart Graffner